Bevacizumab and stereotactic radiosurgery achieved complete response for pediatric recurrent medulloblastoma
- 1 January 2018
- journal article
- research article
- Published by Medknow in Journal of Cancer Research and Therapeutics
- Vol. 14 (10), 789-S792
- https://doi.org/10.4103/jcrt.jcrt_990_15
Abstract
Recurrent medulloblastoma has a very poor prognosis in children regardless of the treatment employed. We report the case of a 3-year-old child with recurrent refractory medulloblastoma who was treated with both bevacizumab and stereotactic radiosurgery (SRS). The boy was found to harbor a tumor in the cerebral posterior fossa in November 2010. Craniotomy was performed to remove the tumor completely. Postoperative pathological examination showed desmoplastic medulloblastoma. Craniospinal radiotherapy and chemotherapy were performed. Three years later, the boy suffered from constant headache again. Magnetic resonance imaging showed seeding of medulloblastoma in the posterior fossa as four masses with diameter ranging from 2 cm to 3 cm. To avoid overdose radiation, we used SRS and anti-angiogenesis therapy. Bevacizumab was given at 10 mg/kg for four times with an interval of 1 month. Gamma Knife (Leksell Gamma Knife®, Elekta Instruments, Stockholm, Sweden) was used targeting at one lesion each time and performed for consecutive two times with bevacizumab therapy. Following this combined treatment, the lesions targeted with radiosurgery showed complete response with minimal toxicity in <1 month successively. The combined use of bevacizumab and SRS may represent a novel treatment against medulloblastoma in patients who are not surgical candidates, and should be investigated further. This is the first documented case of medulloblastoma treated with bevacizumab and SRS. Further clinical trials should be considered to evaluate the effectiveness of this strategy.Keywords
This publication has 15 references indexed in Scilit:
- Phase I Study of Bevacizumab Plus Irinotecan in Pediatric Patients with Recurrent/Refractory Solid TumorsJapanese Journal of Clinical Oncology, 2013
- A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid TumorsPLOS ONE, 2013
- Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experienceChild's Nervous System, 2013
- Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumorsPediatric Blood & Cancer, 2011
- Metastatic Medulloblastoma in Childhood: Chang's Classification RevisitedInternational Journal of Surgical Oncology, 2011
- Incidence, Risks, and Sequelae of Posterior Fossa Syndrome in Pediatric MedulloblastomaInternational Journal of Radiation Oncology*Biology*Physics, 2010
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor AngiogenesisCancer Cell, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Functional VEGF and VEGF receptors are expressed in human medulloblastomasNeuro-Oncology, 2007
- Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastomaJournal of Neurosurgery: Pediatrics, 2007